Genetically engineered bacterium for synthesizing vitamin D3 precursor and application of genetically engineered bacterium
Through genetic engineering technology, the Saccharomyces cerevisiae strains are constructed, and the synthesis pathway of vitamin D3 precursors is optimized, which solves the problem of metabolic flow shunt in biosynthesis, and achieves efficient and green production of vitamin D3 precursors, meeting the growing demand.
Patent Information
- Application Number
- CN202411032398.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-12-06
AI Technical Summary
The metabolic flow shunt of biosynthetic vitamin D3 precursors in the prior art leads to low synthesis efficiency, and existing methods have problems such as environmental pollution and high costs, making it difficult to meet the growing global demand for vitamin D3.
Saccharomyces cerevisiae strains were constructed through genetic engineering technology, DHCR24 reductase encoding genes were introduced, and the mevalonate pathway and postsqualene pathway regulation genes were integrated on the chromosomes, and ergosterol competition pathway genes were knocked out or silenced, and transcription factor expression was optimized. , to improve the synthesis efficiency of vitamin D3 precursor.
It has achieved efficient and green synthesis of vitamin D3 precursors, overcome the problem of metabolic flow shunt, and improves yield, providing a feasible solution for the synthesis of vitamin D3 precursors in a full-biological manner.
Smart Images

Figure CN119081902A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of bioengineering, and in particular to a genetically engineered bacterium for synthesizing a vitamin D3 precursor and an application thereof. Background Art
[0002] Vitamin D, as a fat-soluble vitamin, is one of the important trace elements required by the human body. It can promote the absorption of calcium ions by intestinal cells and thus prevent and treat rickets and osteoporosis. In addition, vitamin D also has the effects of improving human immunity and reducing the incidence of cancer. Vitamin D exists in nature mainly in two forms: vitamin D2 and vitamin D3. The human body obtains metabolites 1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 when it ingests vitamin D2 and vitamin D3, respectively. 1,25-dihydroxyvitamin D2 has no biological activity, while 1,25-dihydroxyvitamin D3 can bind to the vitamin D receptors of more than 30 tissues in the body and regulate the expression of hundreds of genes by regulating multiple metabolic reactions. Therefore, researchers believe that vitamin D3 is more important for humans. Vitamin D3 in the human body mainly comes from two aspects: one is directly obtained from food, such as animal liver, fish oil, eggs, etc., and the other is synthesized by the skin under ultraviolet radiation using 7-dehydrocholesterol (7-DHC) as a substrate.
[0003] However, most of the population is still at risk of insufficient vitamin D3 intake. There are many processes for synthesizing vitamin D3 precursors. The chemical method has problems such as low yield, many by-products, difficult to control conditions, and environmental pollution; although the enzymatic method has mild conversion conditions, it is expensive and difficult to produce on a large scale. With the growing global demand for vitamin D3, there is an urgent need to develop a green and sustainable method for the efficient synthesis of vitamin D3 precursors.
[0004] A Chinese patent document with publication number CN113684141A discloses the construction of a Saccharomyces cerevisiae strain for extracellular transport of squalene, a precursor of vitamin D3, and its application. Squalene is one of the key precursors for the synthesis of vitamin D3. The invention constructs a recombinant Saccharomyces cerevisiae strain Z1O3 with high squalene production. The recombinant Saccharomyces cerevisiae has enhanced expression of 3-hydroxy-3-methylglutaryl-CoA reductase, isopentenyl pyrophosphate isomerase, farnesyl pyrophosphate synthase, and endoplasmic reticulum size regulator-related genes INO2, Pdr5 protein and Osh3 protein; and the ROX1 gene is knocked out; the recombinant Saccharomyces cerevisiae not only has the ability to transport squalene extracellularly, but also has stronger squalene production performance.
[0005] The Chinese patent document with publication number CN114703077A discloses a recombinant yeast engineered strain for producing 7-dehydrocholesterol and its application. The invention uses Saccharomyces cerevisiae CENPK2-1D as the host, completes the knockout of the competitive pathway genes ERG5 and ERG6, and integrates the double copy of the δ(24)-sterol reductase gene DHCR24 from Gallus gallus, preliminarily realizing the synthesis of 7-dehydrocholesterol in Saccharomyces cerevisiae. On this basis, the non-pathway genes MOT3 and NEM1 are knocked out to further improve the accumulation of 7-dehydrocholesterol in Saccharomyces cerevisiae, and the upregulation of the key gene ERG2 is verified by qPCR. By increasing the rate-limiting step genes tHMG1, IDI, ERG2, ERG3, DHCR24 and the multi-copy integration of the cytoplasmic catalase gene CTT1, the accumulation of 7-dehydrocholesterol is further increased.
[0006] Although some methods for regulating microbial metabolic pathways to synthesize vitamin D3 precursors have been reported in the prior art, with the deepening of scientific research and the continuous progress in the field of biotechnology, further broadening and enriching the synthesis methods of vitamin D3 precursors will not only help to better understand the biological mechanism of vitamin D3 precursor synthesis, but also provide more efficient, environmentally friendly and economically feasible alternatives for industrial production. Summary of the invention
[0007] In order to overcome the problem of metabolic flow diversion of biosynthetic vitamin D3 precursor in the prior art, the present invention provides a genetically engineered bacterium for synthesizing vitamin D3 precursor and a method for green and efficient synthesis of vitamin D3 precursor.
[0008] The specific technical solutions adopted are as follows:
[0009] A genetically engineered bacterium for synthesizing a vitamin D3 precursor is obtained by genetically modifying Saccharomyces cerevisiae as a starting strain, wherein the genetic modification method comprises:
[0010] (1) introducing a gene encoding DHCR24 reductase;
[0011] (2) integration of at least one of the mevalonate pathway regulatory genes ERG10, ERG13, HMGR, ERG12, ERG8, ERG19, IDI1, and ERG20 on the chromosome;
[0012] (3) integration of at least one of the post-squalene pathway regulatory genes ERG7, ERG11, ERG24, ERG25, ERG26, ERG27, ERG1, ERG2, and ERG3 on the chromosome;
[0013] (4) knocking out, silencing or weakening the expression of ergosterol competition pathway regulatory genes, wherein the ergosterol competition pathway regulatory genes include at least one of ERG5, ERG6, ERG2, and ERG3;
[0014] (5) Optimizing the expression of transcription factors. The method of optimizing the expression of transcription factors is to knock out or silence at least one of the ROX1 gene and the MOT3 gene, and / or overexpress at least one of the UPC2 gene, the ECM22 gene, and the HAP1 gene.
[0015] The D3 precursor includes yeast sterol and / or 7-dehydrocholesterol.
[0016] Preferably, in method (2), the mevalonate pathway regulatory genes HMGR, ERG20 and IDI1 are integrated on the chromosome, or the mevalonate pathway regulatory genes HMGR, ERG20 and ERG12 are integrated.
[0017] Preferably, in embodiment (3), the squalene pathway regulatory genes ERG1 and ERG11 are integrated on the chromosome.
[0018] Preferably, in method (4), the expression of ergosterol competition pathway regulatory genes ERG5 and ERG6 is knocked out, silenced or weakened.
[0019] Specifically, the Gene ID of the gene encoding DHCR24 reductase is 424661, the Gene ID of the ERG10 gene is 856079, the Gene ID of the ERG13 gene is 854913, the Gene ID of the HMGR gene is 854900, the Gene ID of the ERG12 gene is 855248, the Gene ID of the ERG8 gene is 855260, the Gene ID of the ERG19 gene is 855779, the Gene ID of the IDI1 gene is 855986, the Gene ID of the ERG20 gene is 853272, the Gene ID of the ERG7 gene is 856470, the Gene ID of the ERG11 gene is 856398, the Gene ID of the ERG24 gene is 855441, the Gene ID of the ERG25 gene is 852951, the Gene ID of the ERG26 gene is 852883, and the Gene ID of the ERG27 gene is The Gene ID is 850790, the Gene ID of ERG1 is 853086, the Gene ID of ERG2 gene is 855242, the Gene ID of ERG3 gene is 850745, the Gene ID of ERG5 gene is 855029, the Gene ID of ERG6 gene is 855003, the Gene ID of UPC2 gene is 851799, the Gene ID of ECM22 gene is 850928, the Gene ID of HAP1 gene is 850958, and the Gene ID of MOT3 gene is 855092.
[0020] Preferably, the GAL1,10 bidirectional promoter is used to regulate IDI1, ERG12, ERG20, ERG1, DHCR24, Emp22, and HAP1, respectively, the GAL2 promoter is used to regulate HMGR, ERG11, and UPC2, respectively, and the promoter HXT1 is used to regulate ERG5 and ERG6. The Gene IDs of promoters GAL1 and GAL2 are 852308 and 850770, respectively, the Gene ID of GAL10 is 852307, and the Gene ID of HXT1 is 856494.
[0021] The present invention also provides a method for constructing the genetically engineered bacteria, comprising: using Saccharomyces cerevisiae as a starting strain, inserting into the genome or using a recombinant expression plasmid to introduce a DHCR24 reductase coding gene, a mevalonate pathway regulatory gene, and a post-squalene pathway regulatory gene, and using biological technology to knock out, silence or weaken the expression of ergosterol competition pathway regulatory genes in the genome, and optimizing the expression of transcription factors to obtain the genetically engineered bacteria.
[0022] Specifically, using wild-type Saccharomyces cerevisiae CEN.PK 2-1D as a starting strain, inserting into the genome or introducing using a recombinant expression plasmid a gene encoding DHCR24 reductase to obtain strain CDS0;
[0023] Furthermore, the mevalonate pathway regulatory genes HMGR, ERG20, and IDI1 were integrated into the chromosome of strain CDS0 to obtain strain CDS1;
[0024] Furthermore, the mevalonate pathway regulatory genes HMGR, ERG20, and ERG12 were integrated into the chromosome of strain CDS0 to obtain strain CDS2;
[0025] Furthermore, the post-squalene pathway regulatory genes ERG1 and ERG11 were integrated into the chromosome of strain CDS1 to obtain strain CDS3;
[0026] Furthermore, the post-squalene pathway regulatory genes ERG1 and ERG11 were integrated into the chromosome of strain CDS2 to obtain strain CDS4;
[0027] Furthermore, the expression of the ergosterol competition pathway regulatory gene ERG5 in strain CDS3 was knocked out or weakened to obtain strains CDS9 and CDS10, respectively;
[0028] Furthermore, the expression of the ergosterol competition pathway regulatory gene ERG5 in strain CDS4 was knocked out or weakened to obtain strains CDS11 and CDS12, respectively;
[0029] Furthermore, the expression of the ergosterol competition pathway regulatory gene ERG6 in strain CDS9 was knocked out or weakened to obtain strains CDS13 and CDS14, respectively;
[0030] Furthermore, the expression of the ergosterol competition pathway regulatory gene ERG6 in strain CDS10 was knocked out or weakened to obtain strains CDS15 and CDS16, respectively;
[0031] Furthermore, the expression of the ergosterol competition pathway regulatory gene ERG6 in strain CDS11 was knocked out or weakened to obtain strains CDS17 and CDS18, respectively;
[0032] Furthermore, the expression of the ergosterol competition pathway regulatory gene ERG6 in strain CDS12 was knocked out or weakened to obtain strains CDS19 and CDS20, respectively;
[0033] Furthermore, the ROX1 gene in CDS14 was knocked out to obtain strain CDS21;
[0034] Furthermore, the UPC2 gene, ECM22 gene, and HAP1 gene in strain CDS21 were overexpressed to obtain strains CDS22, CDS23, and CDS24, and the MOT3 gene in CDS21 was knocked out to obtain strain CDS25;
[0035] Furthermore, the ECM22 gene in strain CDS22 was overexpressed to obtain strain CDS26.
[0036] The present invention also provides the use of the genetically engineered bacteria in producing vitamin D3 precursors.
[0037] The present invention also provides a method for synthesizing a vitamin D3 precursor, which is prepared by fermentation using the genetically engineered bacteria. The genetically engineered bacteria provided by the present invention overcome the problem of metabolic flow diversion of biosynthetic vitamin D3 precursors, and are conducive to increasing the yield of vitamin D3 biosynthesis.
[0038] The invention also provides the application of the genetically engineered bacteria in the fields of food, medicine or chemical industry.
[0039] Compared with the prior art, the present invention has the following beneficial effects:
[0040] (1) The genetically engineered bacteria constructed by the method of the present invention overcome the current problem of metabolic flow diversion in the biosynthesis of vitamin D3 precursors. By exploring the optimal expression mode of the competing pathways, a method for synthesizing vitamin D3 precursors by a fully biological method is provided, thereby improving the efficiency of vitamin D3 precursor synthesis.
[0041] (2) The method provided by the present invention for synthesizing vitamin D3 precursor by fermentation using genetically engineered bacteria is green and efficient, and strengthens the metabolic flow of vitamin D3 precursor, optimizes the expression of cofactors, and increases the yield of vitamin D3 precursor. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1 The biological metabolic pathway for the synthesis of vitamin D3 precursor by Saccharomyces cerevisiae using glucose as carbon source.
[0043] Figure 2 This is a statistical chart of the production of 7-DHC synthesized by strains CDS0, CDS1 and CDS2.
[0044] Figure 3 This is a statistical chart of the production of 7-DHC produced by strains CDS3 and CDS4.
[0045] Figure 4 This is a statistical chart of the production of 7-DHC fermented by strains CDS9, CDS10, CDS11 and CDS12.
[0046] Figure 5This is a statistical chart of the production of 7-DHC fermented by strains CDS13, CDS14, CDS15, CDS16, CDS17, CDS18, CDS19, and CDS20.
[0047] Figure 6 This is a statistical chart of the production of 7-DHC fermented by strains CDS21, CDS22, CDS23, CDS24, CDS25, and CDS26. DETAILED DESCRIPTION
[0048] The present invention is further illustrated below in conjunction with the examples and accompanying drawings. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The operating methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer.
[0049] The materials and methods involved in the following embodiments are as follows:
[0050] (1) Culture medium
[0051] YPD liquid medium (1L): 20g peptone, 10g yeast extract and 20g glucose, autoclaved at 121°C for 20 minutes. YPD solid medium: Add 2% (m / v) agar powder to YPD liquid medium and autoclave at 121°C for 20 minutes. LB liquid medium (1L): 5g yeast extract, 10g tryptone, 10g sodium chloride, autoclaved at 121°C for 20 minutes. LB solid medium: Add 2% (m / v) agar powder to LB liquid medium and autoclave at 121°C for 20 minutes. SD liquid medium (1L): 20g glucose, 6.7g amino-free yeast nitrogen source, autoclaved at 121°C for 20 minutes. SD solid medium: Add 2% (m / v) agar powder to SD liquid medium and autoclave at 121°C for 20 minutes. Pentafluoroorotic acid solid medium: weigh 100 mg of pentafluoroorotic acid, add 1 mL of dimethyl sulfoxide and immediately shake to dissolve, sterilize by filtration. Add the solution after filtration to 100 mL of liquid SD solid medium, and then add 0.1 mL of sterilized histidine solution (20 g / L) and 1 mL of sterilized uracil solution (20 g / L).
[0052] (2) Preparation of competent cells of Saccharomyces cerevisiae
[0053] Take out the frozen stock of Saccharomyces cerevisiae (wild-type Saccharomyces cerevisiae CEN.PK 2-1D) to be transformed from the -80℃ ultra-low temperature freezer, streak on a YPD solid plate and culture in a 30℃ incubator for 48h. Pick a single colony on the YPD plate and culture it in a 2mL YPD liquid medium at 30℃ and 220×g shaking incubator for 15h. Determine the OD600 value of the bacterial solution, transfer it to 20mL YPD liquid medium so that the initial OD600 value is 0.1, and culture it in a 30℃, 220×g shaking incubator for 5-6h to make the OD600 value reach 0.7-1. Take 10mL of bacterial solution and centrifuge at 1000×g for 5min, discard the supernatant and resuspend the bacteria with 1mL of sterile water, centrifuge at 1500×g for 1min, discard the supernatant and resuspend the bacteria with 1mL of 0.1M lithium acetate solution, centrifuge at 1500×g for 1min, discard the supernatant and resuspend the bacteria with 0.2mL of sterile water, divide into four portions, add 250mL of 20% glycerol solution to each portion, and store in a -80℃ refrigerator.
[0054] (3) Transformation of Saccharomyces cerevisiae
[0055] Take out the frozen Saccharomyces cerevisiae competent cells to be transformed from the -80 refrigerator and thaw on ice. Take ssDNA and place it in a boiling water bath for 5 minutes, then put it on ice for later use. Centrifuge the thawed Saccharomyces cerevisiae competent cells at 1000×g for 1 minute and discard the supernatant. Add 240mL of PEG solution, 36μL of 1M lithium acetate solution, and 10μL of ssDNA to the precipitate in sequence, then add the gRNA plasmid (500ng) and donor (1000ng) to be transformed, make up to 360μL with sterile water, blow the system evenly, incubate at 30℃ for 30min, heat shock at 42℃ for 20min, and centrifuge at 1000×g for 1min. After discarding the supernatant, add 100μL of sterile water to resuspend, plate the bacteria on SD plates, and culture in a 30℃ incubator.
[0056] (4) The strain information involved in the embodiment is shown in Table 1
[0057] Table 1 Strain information involved in the examples
[0058]
[0059]
[0060]
[0061] Example 1 Construction of Saccharomyces cerevisiae strains CDS0, CDS1 and CDS2
[0062] The chicken-derived DHCR24 reductase (coding gene Gene ID: 424661) was expressed in the Saccharomyces cerevisiae plasmid pESC, and the restriction endonucleases SalI and BamHI were used to excise the pESC plasmid multiple cloning restriction enzyme sites to make the plasmid pESC a linearized vector. After amplifying DHCR24 using primers DHCR24F and DHCR24R with SalI and BamHI linkers, the linearized vector and the amplified and purified DHCR24 were transformed in Escherichia coli and named pDHCR24 plasmid. The pDHCR24 plasmid was transformed into the Saccharomyces cerevisiae CEN.PK2-1D strain, and the resulting strain was named CDS0, and inoculated into 20mL YPD liquid culture medium at a bacterial concentration of OD600 0.1, and fermented at 30°C 200rpm for 96h. HPLC detection obtained 10mg / L 7-DHC, realizing the de novo synthesis of vitamin D3 precursor (from glucose as a carbon source) by Saccharomyces cerevisiae. Figure 1 ).
[0063] Based on the Saccharomyces cerevisiae strain CDS0, one copy of the mevalonate pathway genes HMGR, ERG20, IDI1 and HMGR, ERG20, ERG12 were expressed on chromosome IX of CDS0 using the GAL2, GAL1, and GAL10 promoters, respectively. The genome of Saccharomyces cerevisiae CEN.PK2-1D was used as a template and the primers IX-1UP-F, GAL2-F, GAL2-R, HMGR1-F, HMGR1-R, DIT1-F, DIT1-R, PRM9-F, PRM9-R, IDI1-F, IDI1-R, GAL1-F, GAL1-R, ERG20-F, ERG20-R, CYC1-F, CYC1-R, IX1DOWN-F, IX1DOWN-R were used to confer a restriction endonuclease inhibitor on the DNA donor IX1UP-P. GAL2 -HMGR1-T DIT1 -T PRM9 -IDI1-P GAL10-1 -ERG20-T CYC1-IX1DOWN was used for PCR amplification, and 1000ng of DNA donor was transformed into the competent cells of Saccharomyces cerevisiae strain CDS0. After culturing at 30℃ for 72h, a single clone was picked and cultured at 30℃ for 15h. The genome was extracted from the cultured bacterial solution for PCR verification. The primers used were GCCAATGACTGCAAATACGTTCG and GTTTCGCCATAGCCATGTGCC (same as the IX-1UP-F sequence). The verified strain was streaked on a pentafluoroorotic acid plate, cultured at 30℃ for 84h to lose the plasmid, and then a single clone was picked for culture and preservation to obtain strains CDS1 and CDS2. CDS1 and CDS2 were inoculated into 20mL YPD liquid culture medium at a bacterial concentration of OD600 0.1, and fermented at 30℃ and 200rpm for 96h. HPLC detection obtained 37mg / L and 29mg / L of 7-DHC ( Figure 2 ).
[0064] The introduced sequences involved in this embodiment are shown in Table 2;
[0065] Table 2 Primer sequences (SEQ ID NO.1-SEQ ID NO.24)
[0066]
[0067]
[0068] Example 2 Construction of Saccharomyces cerevisiae strains CDS3 and CDS4
[0069] Based on the Saccharomyces cerevisiae strains CDS1 and CDS2, the post-squalene pathway genes ERG11 and ERG1 were expressed using the GAL2 promoter and the GAL1 promoter, respectively. The Saccharomyces cerevisiae CEN.PK2-1D genome was used as a template and the DNA donor IX2UP-P was amplified using primers IX-2UP-F, IX-2UP-R, ERG11-F, ERG11-R, ERG1-F, ERG1-R, PRM9-F, and PRM9-R. GAL2 -ERG11-T CYC1 -T DIT1 -P GAL10-1 -ERG1-T PRM9-IX2DOWN (the gene primers mentioned above will not be repeated, the same below), use the cerevisiae yeast strains CDS1 and CDS2 to streak on the YPD plate, culture at 30℃ for 48h, pick a single clone and culture it in YPD liquid medium at 30℃ and 200rpm for 15h, use CDS1 and CDS2 to prepare competent cells, transform 1000ng DNA donor into CDS1 and CDS2 competent cells, culture at 30℃ for 72h, pick a single clone and culture it at 30℃ for 15h, extract the genome from the cultured bacterial solution and perform PCR verification, the verification primers are CATGGCCTTTAGGTCATGACG and CCTCTAGCGAAAGAAAAAGTGGTCC. The verified strains were streaked on the pentafluoroorotic acid plate, cultured at 30℃ for 84h to lose the plasmid, and then pick a single clone to culture and preserve the bacteria to obtain strains CDS3 and CDS4. CDS3 and CDS4 were inoculated into 20 mL YPD liquid medium at a bacterial concentration of OD600 0.1 and fermented at 30°C and 200 rpm for 96 h. HPLC analysis revealed 73 mg / L and 65 mg / L 7-DHC ( Figure 3 ).
[0070] The introduced sequences involved in this embodiment are shown in Table 3;
[0071] Table 3 Primer sequences (SEQ ID NO.25-SEQ ID NO.32)
[0072]
[0073] Example 3 Construction of Saccharomyces cerevisiae strains CDS9, CDS10, CDS11 and CDS12
[0074] Based on the Saccharomyces cerevisiae strains CDS3 and CDS4, the ERG5 gene was knocked out and weakened. The genome of Saccharomyces cerevisiae CEN.PK2-1D was used as a template, and primers ERG5UP-F, ERG5UP-R, ERG5DW-F, ERG5DW-R, HXT1-F, and HXT1-R were used to knock out the ERG5 gene ERG5UP-ERG5DOWN and weaken the ERG5UP-T PRM9 -P HXT1 -ERG5DOWNDNA donors were amplified by streaking YPD plates with Saccharomyces cerevisiae strains CDS3 and CDS4, respectively, and culturing at 30°C for 48 h. Single clones were picked and cultured in YPD liquid medium at 30°C and 200 rpm for 15 h. Competent cells were prepared using CDS3 and CDS4, respectively, and the ERG5 gene knockout donor ERG5UP-ERG5DOWN and the ERG5 gene attenuation donor ERG5UP-T were respectively amplified. PRM9 -P HXT1-ERG5DOWN was transformed into the competent cells of Saccharomyces cerevisiae strains CDS3 and CDS4. After culturing at 30°C for 72 hours, a single clone was picked and cultured at 30°C for 15 hours. The genome was extracted from the cultured bacterial solution for PCR verification. The verification primers were GGAACGCGAAGACAGACGTAC and GGTTGTGAACGTGGGAGGTTC. The verified strain was streaked on a pentafluoroorotic acid plate, cultured at 30°C for 84 hours to lose the plasmid, and then a single clone was picked for culture and preservation to obtain strains CDS9, CDS10, CDS11, and CDS12. CDS9, CDS10, CDS11, and CDS12 were inoculated into 20 mL YPD liquid culture medium at a bacterial concentration of OD6000.1, respectively, and fermented at 30°C and 200rpm for 96 hours. HPLC detection obtained 120 mg / L, 98 mg / L, 65 mg / L, and 103 mg / L of 7-DHC ( Figure 4 ).
[0075] The introduced sequences involved in this embodiment are shown in Table 4;
[0076] Table 4 Primer sequences (SEQ ID NO.33-SEQ ID NO.40)
[0077]
[0078]
[0079] Example 4 Construction of Saccharomyces cerevisiae strains CDS13, CDS14, CDS15, CDS16, CDS17, CDS18, CDS19, CDS20
[0080] Based on the Saccharomyces cerevisiae strains CDS9, CDS10, CDS11, and CDS12, the ERG6 gene was knocked out and weakened. The genome of Saccharomyces cerevisiae CEN.PK2-1D was used as a template, and the primers ERG6UP-F, ERG6UP-R, ERG6DW-F, and ERG6DW-R were used to knock out the ERG6 gene. The DNA donor ERG6UP-ERG6DOWN and the attenuation DNA donor ERG6UP-T were used. PRM9 -P HXT1 -ERG6DOWN, the YPD plates were streaked with Saccharomyces cerevisiae strains CDS9, CDS10, CDS11, and CDS12, respectively, and cultured at 30°C for 48 h. Single clones were picked and cultured in YPD liquid medium at 30°C and 200 rpm for 15 h. Competent cells were prepared using CDS9, CDS10, CDS11, and CDS12, respectively, and the ERG6 gene knockout donor ERG6UP-ERG6DOWN and the ERG6 gene attenuation donor ERG6UP-T were respectively cloned. PRM9 -PHXT1 -ERG6DOWN was transformed into the competent cells of Saccharomyces cerevisiae strains CDS9, CDS10, CDS11, and CDS12. After culturing at 30°C for 72 hours, a single clone was picked and cultured at 30°C for 15 hours. The genome was extracted from the cultured bacterial solution and PCR verified using the primers CCGGGGCTCGTGCTTATTC and GAAAAGATGCAACAGGGTAAGATCAGC. The verified strains were streaked on pentafluoroorotic acid plates, cultured at 30°C for 84 hours to lose the plasmid, and then a single clone was picked for culture and preservation to obtain strains CDS13, CDS14, CDS15, CDS16, CDS17, CDS18, CDS19, and CDS20. CDS13, CDS14, CDS15, CDS16, CDS17, CDS18, CDS19, and CDS20 were inoculated into 20 mL YPD liquid medium at a bacterial concentration of OD600 0.1, and fermented at 30°C, 200 rpm for 96 h. HPLC analysis revealed that 170 mg / L, 210 mg / L, 100 mg / L, 130 mg / L, 110 mg / L, 85 mg / L, 102 mg / L, and 98 mg / L of 7-DHC were obtained, respectively. Figure 5 ).
[0081] The introduced sequences involved in this embodiment are shown in Table 5;
[0082] Table 5 Primer sequences (SEQ ID NO.41-SEQ ID NO.46)
[0083]
[0084] Example 5 Construction of Saccharomyces cerevisiae strain CDS21
[0085] Based on the Saccharomyces cerevisiae strain CDS14, the gene knockout of ROX1 was carried out. The genome of Saccharomyces cerevisiae CEN.PK2-1D was used as a template, and the primers ROX1UP-F, ROX1UP-R, ROX1DW-F, and ROX1DW-R were used to amplify the DNA donor ROX1UP-ROX1DOWN. The Saccharomyces cerevisiae strain CDS14 was streaked on a YPD plate and cultured at 30°C for 48 h. A single clone was picked and cultured in YPD liquid medium at 30°C and 200 rpm for 15 h. Competent cells were prepared using CDS14, and 1000 ng of the homologous recombination fragment of the ROX1 gene knockout donor ROX1UP-ROX1DOWN was transformed into CDS14 competent cells. After culturing at 30°C for 72 h, a single clone was picked and cultured at 30°C for 15 h. The genome extracted from the cultured bacterial liquid was verified by PCR. The verification primers were GCAATTGCAGAAGCTTTCCCTGAG and GGATGAGTAAGGTGTTCGTTCTACTTC. The verified strain was streaked on a pentafluoroorotic acid plate, cultured at 30°C for 84 hours to lose the plasmid, and then a single clone was picked for culture and preservation to obtain strain CDS21. CDS21 was inoculated into 20 mL YPD liquid medium at a bacterial concentration of OD600 0.1, and fermented at 30°C and 200 rpm for 96 hours. HPLC detection obtained 325 mg / L of 7-DHC.
[0086] The introduced sequences involved in this embodiment are shown in Table 6;
[0087] Table 6 Primer sequences (SEQ ID NO.47-SEQ ID NO.52)
[0088]
[0089] Example 6 Construction of Saccharomyces cerevisiae strains CDS22, CDS23, CDS24, CDS25
[0090] Based on the Saccharomyces cerevisiae strain CDS21, UPC2, ECM22, and HAP1 were overexpressed and MOT3 was knocked out. The genome of Saccharomyces cerevisiae CEN.PK2-1D was used as a template and primers XI-1UP-F, XI-1UP-R, XI-1DW-F, XI-1DW-R, UPC2-F, UPC2-R, ECM22-F, ECM22-R:, HAP1-F, HAP1-R, MOTUP-F, MOTUP-R, MOTDW-F, MOTDW-R were used as DNA donors, respectively. GAL2 -UPC2-T PRM9 -XI1DOWN, XI1UP-P GAL2 -ECM22-T PRM9-XI1DOWN, XI1UP-P GAL2 -HAP1-T PRM9 -XI1DOWN, MOT3UP-MOT3DOWN, the YPD plates were streaked with the Saccharomyces cerevisiae strain CDS21 and cultured at 30°C for 48 h. Single clones were picked and cultured in YPD liquid medium at 30°C and 200 rpm for 15 h. Competent cells were prepared using CDS21. One copy of the UPC2 gene DNA donor XI1UP-P GAL2 -UPC2-T PRM9 -XI1DOWN 1000ng homologous recombination fragment, ECM22 gene DNA donor XI1UP-P GAL2 -ECM22-T PRM9 -XI1DOWN 1000ng homologous recombination fragment, HAP1 gene DNA donor XI1UP-P GAL2 -HAP1-T PRM9 -XI1DOWN 1000ng homologous recombination fragment and MOT3 DNA donor MOT3UP-MOT3DOWN 1000ng homologous recombination fragment were transformed into CDS21 competent cells. After culture at 30℃ for 72h, single clones were picked and cultured at 30℃ for 15h. The genome was extracted from the cultured bacterial liquid for PCR verification. The verification primers for overexpression of UPC2, ECM22, and HAP1 genes were GAATAGTGACGTTGTGATGCGG and CTTCCACGGAATACCAAGCCC, and the verification primers for knockout of MOT3 gene were GCGCGACTCGAATCCTTGAC and CAGTTCATCAATGTGGGTGGTATGG. The verified correct strain was streaked on pentafluoroorotic acid plates, cultured at 30°C for 84 hours to lose the plasmid, and then a single clone was picked for culture and preservation to obtain strains CDS22, CDS23, CDS24 and CDS25; CDS22, CDS23, CDS24 and CDS25 were inoculated into 20 mL YPD liquid culture medium at a bacterial concentration of OD600 0.1, fermented at 30°C and 200 rpm for 96 hours, and HPLC detection obtained 410 mg / L, 360 mg / L, 120 mg / L and 320 mg / L of 7-DHC.
[0091] The introduced sequences involved in this embodiment are shown in Table 7;
[0092] Table 7 Primer sequences (SEQ ID NO.53-SEQ ID NO.70)
[0093]
[0094] Example 7 Construction of Saccharomyces cerevisiae strain CDS26
[0095] Based on the Saccharomyces cerevisiae strain CDS22, ECM22 was overexpressed. The genome of Saccharomyces cerevisiae CEN.PK2-1D was used as a template, and primers XI-2UP-F, XI-2UP-R, CYC1-F, CYC1-R, XI-2DW-F, and XI-2DW-R were used to amplify the DNA donor XI2UP-PGAL2-ECM22-TCYC1-XI2DOWN. The Saccharomyces cerevisiae strain CDS22 was streaked on a YPD plate and cultured at 30°C for 48 h. A single clone was picked and cultured in YPD liquid medium at 30°C and 200 rpm for 15 h. Competent cells were prepared using CDS22, and one copy of the ECM22 gene DNA donor XI2UP-PGAL2-ECM22-TCYC1-XI2DOWN was amplified. 1000ng homologous recombination fragment was transformed into CDS22 competent cells, and after culturing at 30℃ for 72h, a single clone was picked and cultured at 30℃ for 15h. The genome was extracted from the cultured bacterial solution for PCR verification. The verification primers were CATGGCCTTTAGGTCATGACG (verification primer-3) and CCTCTAGCGAAAGAAAAAGTGGTCC (verification primer-4). The verified strain was streaked on a pentafluoroorotic acid plate, cultured at 30℃ for 84h to lose the plasmid, and then a single clone was picked for culture and preservation to obtain strain CDS26. CDS26 was inoculated into 20mL YPD liquid culture medium at a bacterial concentration of OD600 0.1, and fermented at 30℃ and 200rpm for 96h. HPLC detection obtained 480mg / L 7-DHC ( Figure 6 ).
[0096] The introduced sequences involved in this embodiment are shown in Table 8;
[0097] Table 8 Primer sequences (SEQ ID NO.71-SEQ ID NO.74)
[0098]
[0099] Example 8 Parallel bioreactor fed-batch fermentation
[0100] The batch-fed fermentation used a 1L parallel bioreactor system, and the batch-fed fermentation volume was 0.4L. The batch-fed fermentation strain was CDS26. The frozen CDS26 glycerol bacteria were streaked on the YPD plate and cultured at 30℃ for 60h. A single colony was picked and cultured in 4mL YPD liquid medium at 30℃ and 200rpm for 15h, then inoculated into 50mL YPD liquid medium, cultured at 30℃ and 200rpm for 24h, and then inoculated into the fermenter after 24h. The initial OD600 was 0.4, the pH was 5.6, the culture temperature was 30℃, and the speed was 400rpm. The feed medium used YPD medium, and the initial glucose concentration was 20g / L. The feeding method used exponential feeding, μ=0.05. When the glucose was consumed in the batch-fed fermentation, exponential feeding began, and the glucose concentration after feeding was 20g / L. After 196 hours of batch-fed fermentation, the CDS26 engineered bacteria 7-DHC production was 3g / L.
[0101] The embodiments described above provide a detailed description of the technical solutions of the present invention. It should be understood that the above are only specific embodiments of the present invention and are not intended to limit the present invention. Any modifications, supplements or similar substitutions made within the scope of the principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A genetically engineered bacterium for synthesizing a vitamin D3 precursor, It is characterized in that The genetically engineered bacteria are obtained by genetically modifying the yeast Saccharomyces cerevisiae as a starting strain, and the genetic modification method includes: (1) introducing a gene encoding DHCR24 reductase; (2) integration of at least one of the mevalonate pathway regulatory genes ERG10, ERG13, HMGR, ERG12, ERG8, ERG19, IDI1, and ERG20 on the chromosome; (3) integration of at least one of the post-squalene pathway regulatory genes ERG7, ERG11, ERG24, ERG25, ERG26, ERG27, ERG1, ERG2, and ERG3 on the chromosome; (4) knocking out, silencing or weakening the expression of ergosterol competition pathway regulatory genes, wherein the ergosterol competition pathway regulatory genes include at least one of ERG5, ERG6, ERG2, and ERG3; (5) Optimizing the expression of transcription factors. The method of optimizing the expression of transcription factors is to knock out or silence at least one of the ROX1 gene and the MOT3 gene, and / or overexpress at least one of the UPC2 gene, the ECM22 gene, and the HAP1 gene.
2. The genetically engineered bacterium according to claim 1, It is characterized in that In method (2), the mevalonate pathway regulatory genes HMGR, ERG20 and IDI1 are integrated on the chromosome, or the mevalonate pathway regulatory genes HMGR, ERG20 and ERG12 are integrated.
3. The genetically engineered bacteria according to claim 1, It is characterized in that In approach (3), the squalene pathway regulatory genes ERG1 and ERG11 are integrated on the chromosome.
4. The genetically engineered bacterium according to claim 1, It is characterized in that In method (4), the expression of ergosterol competition pathway regulatory genes ERG5 and ERG6 is knocked out, silenced or weakened.
5. The genetically engineered bacterium according to claim 1, It is characterized in that The Gene ID of the gene encoding DHCR24 reductase is 424661, the Gene ID of the ERG10 gene is 856079, the Gene ID of the ERG13 gene is 854913, the Gene ID of the HMGR gene is 854900, the Gene ID of the ERG12 gene is 855248, the Gene ID of the ERG8 gene is 855260, the Gene ID of the ERG19 gene is 855779, the Gene ID of the IDI1 gene is 855986, the Gene ID of the ERG20 gene is 853272, the Gene ID of the ERG7 gene is 856470, the Gene ID of the ERG11 gene is 856398, the Gene ID of the ERG24 gene is 855441, the Gene ID of the ERG25 gene is 852951, the Gene ID of the ERG26 gene is 852883, the Gene ID of the ERG27 gene is 850790, and the Gene ID of the ERG1 The Gene ID is 853086, the Gene ID of ERG2 gene is 855242, the Gene ID of ERG3 gene is 850745, the Gene ID of ERG5 gene is 855029, the Gene ID of ERG6 gene is 855003, the Gene ID of UPC2 gene is 851799, the Gene ID of ECM22 gene is 850928, the Gene ID of HAP1 gene is 850958, and the Gene ID of MOT3 gene is 855092.
6. The method for constructing a genetically engineered bacterium according to any one of claims 1 to 5, It is characterized in that include: Using Saccharomyces cerevisiae as a starting strain, the coding gene of DHCR24 reductase, mevalonate pathway regulatory gene, and post-squalene pathway regulatory gene are inserted into the genome or introduced using a recombinant expression plasmid, and biological technology is used to knock out, silence or weaken the expression of ergosterol competition pathway regulatory genes in the genome, and at the same time optimize the expression of transcription factors to obtain the genetically engineered bacteria.
7. Use of the genetically engineered bacteria according to any one of claims 1 to 5 in the production of vitamin D3 precursor.
8. A method for synthesizing a vitamin D3 precursor, It is characterized in that It is prepared by fermentation using the genetically engineered bacteria described in any one of claims 1 to 5.
9. Use of the genetically engineered bacteria according to any one of claims 1 to 5 in the fields of food, medicine or chemical industry.
Citation Information
Patent Citations
Construction and application of saccharomyces cerevisiae strain for extracellular transport of vitamin D3 precursor squalene
CN113684141A
Recombinant yeast engineering strain for producing 7-dehydrocholesterol and application
CN114703077A
Cited By
Genetically engineered bacterium for producing 7-DHC and application of genetically engineered bacterium
CN121914885A
